Table 4.

Summary of results from adjusted logistic regression analyses at weeks 4, 12, and 48 and longitudinal analyses in Study GS-US-380-1489 (treatment-naïve)

HIV-SI bothersome symptom	Week 4	Week 12	Week 48	Longitudinal model	Description of longitudinal findings
Fatigue/loss of energy	✓	✓	✓	✓	Decreased prevalence in B/F/TAF group maintained over study period without any changes in prevalence from week 4 to week 48 for either group
Dizzy/lightheadedness	✓		✓		Decreased prevalence in B/F/TAF group, ABC/DTG/3TC group with fluctuating prevalence
Nausea/vomiting	✓	✓		✓	Increased initial prevalence in ABC/DTG/3TC group (at week 4) maintained over study period with decreasing prevalence in both groups from week 4 to week 48
Difficulty sleeping		✓	✓		No differences in prevalence observed between groups from week 4 to week 48
Headaches			✓	‡	Decreased prevalence in B/F/TAF group from week 4 to week 48
Loss of appetite		✓		✓	Decreased prevalence in B/F/TAF group, ABC/DTG/3TC group with fluctuating prevalence
Bloating/pain/gas in stomach			✓	‡	No differences in prevalence observed between groups from week 4 to week 48
Changes in body composition				‡	Slight increased prevalence in B/F/TAF group and a greater increased prevalence in ABC/DTG/3TC group
Weight loss/wasting		✓			No differences in prevalence observed between groups from week 4 to week 48
Poor sleep quality (from PSQI)		✓			Decreased prevalence in B/F/TAF group starting from week 4 and maintained over study period with minimal changes in ABC/DTG/3TC group

ABC/DTG/3TC co-formulated abacavir, dolutegravir, and lamivudine, B/F/TAF co-formulated bictegravir, emtricitabine, and tenofovir alafenamide, HIV-SI HIV Symptom Index, PSQI Pittsburgh Sleep Quality Index

✓ = Statistically significant favoring the B/F/TAF group; ‡ = statistically significant time-by-treatment interaction (i.e., changes over time depend on treatment)